Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
Hepatocellular Carcinoma
How do you choose between Atezolizumab/Bevacizumab (IMbrave 150) versus Durvalumab/Tremelimumab (HIMALAYA) in first-line metastatic hepatocellular cancer?
Related Questions
How do you employ focal therapies in localized hepatocellular carcinoma?
What are your top takeaways in GI Cancers from ASCO 2023?
Is the increase in RFS seen with adjuvant atezo/bev in IMbrave050 enough to change practice in resected HCC?
In which situations do you omit the 5FU bolus in FOLFOX or FOLFIRI?
Would you offer adjuvant chemotherapy after SBRT for biopsy proven sub centimeter metastatic pulmonary nodule from rectal cancer?
How would you treat an MSI-H metastatic cholangiocarcinoma found on liquid biopsy?
How do you manage patients with suspected cholangiocarcinoma that presents with biliary obstruction but has repeated negative brushings/biopsies?
Would you offer adjuvant chemotherapy or radiation to a resected MSS T3N0 high-rectal lesion with low anterior resection without pre-op therapy?
For inoperable cholangiocarcinoma, do you recommend up-front chemotherapy prior to offering SBRT or combination chemoradiation?
How do you approach a low grade intra-cholecystic papillary neoplasm of the gallbladder without invasive component and reported surgical pathology with negative margins ?
